Dr. Rafael Carbunaru and his team at Boston Scientific (NYSE:BSX) have spent the last twenty years building, among other things, the Vercise deep brain stimulation system in an attempt to deliver precise, personalized therapy for people with Parkinson’s disease. “It’s a labor of love,” the VP of R&D told MassDevice.com. Carbunaru estimated there are roughly 1.2 […]
Cardiologist questions use of Boston Scientific Watchman device
A Philadelphia cardiologist has written a newspaper column questioning the efficacy and cost of Boston Scientific’s Watchman device for stroke prevention. The Watchman left atrial appendage closure device is designed to prevent blood clots that form in the heart’s left atrial appendage from reaching the brain. Boston Scientific (NYSE:BSX) markets it as an alternative to blood-thinning […]
How one medtech company is working on solving the data dilemma
The electronic medical record was designed to better track patient care, but it has had unintended consequences. Physicians are bombarded with digital patient information all day long, reducing their patient eye-to-eye interactions and adding hours to their workday. A 2016 American Medical Association study found that physicians spent about two hours on electronic health record […]
Boston Scientific to deal microspheres to Varian Medical for $90m
UPDATED July 2, 2019, with financial details, comment from Varian. Looking to mollify anti-trust regulators about its pending $4 billion merger with BTG (LON:BTG), Boston Scientific (NYSE:BSX) said today that it agreed to deal its microsphere assets to Varian Medical (NYSE:VAR) for $90 million. The deal for the drug-eluting and “bland” embolic microsphere business includes Marlborough, Mass.-based Boston […]
Study: Boston Sci’s Watchman cheaper than drugs long-term
Updated to include comments from the principal investigator. A new study has found that use of the Boston Scientific (NYSE:BSX) Watchman left atrial appendage closure (LAAC) device to treat atrial fibrillation costs less than existing and novel anticoagulant drugs over five years. Researchers conducted the analysis using an Excel-based simulation model developed to assess the […]
Boston Scientific adds 600 employees in Costa Rica
Boston Scientific (NYSE:BSX) is reportedly hiring 600 people at two of its Costa Rica facilities. The Marlborough, Mass.-based company plans to hire workers with different levels of educational backgrounds, including those with sixth-grade levels of schooling, professional engineering graduates, finance, accounting and other positions. Boston Scientific will hire employees for its La Aurora de Heredia and […]
Sterigenics moves to upgrade shuttered device sterilization plant
Sterigenics said today that it has applied for permits to upgrade emissions controls at its Willowbrook, Ill. medical device sterilization plant, which had sterilized thousands of devices daily until its Feb.15 shutdown. The Illinois Environmental Protection Agency (EPA) closed the Willowbrook plant, citing excessive emissions of the sterilant ethylene oxide (EO), based on a federal […]
Wall Street shrugs as Boston Scientific sets growth goals
Wall Street shrugged today after Boston Scientific (NYSE:BSX) set out its long-term financial goals, despite a revenue growth target that’s right in line with the consensus. The Marlborough, Mass.-based medical device maker said it’s eyeing double-digit adjusted earnings per share from 2019 to 2022, on an organic compound annual growth rate of 6% to 9% during […]
Boston Scientific opens Irish facility
Boston Scientific (NYSE:BSX) yesterday announced that it officially opened its new Galway, Ireland facility. The Marlborough, Mass.-based company’s €60 million expansion will house 250 employees in the three-story building, according to the Galway Daily newspaper. Get the full story on our sister site, Medical Design & Outsourcing.
FDA panel wants more, better data on paclitaxel-eluting devices
An FDA advisory panel on paclitaxel-eluting devices for treating peripheral artery disease yesterday found that the mortality signal indicated by a meta-analysis last year exists but that further study is needed to determine whether it’s a class effect and to pin down the cause of death. A meta-analysis published in the Journal of the American Heart Assn. last December […]
FDA panel finds ‘smoking gun, but no bullet or dead bodies’ in paclitaxel devices
Members of an FDA advisory panel yesterday cited conflicting evidence from studies of paclitaxel-eluting devices in treating peripheral artery disease, with the panel’s chairman calling the data “a smoking gun, but no bullet or dead bodies at this particular point.” A meta-analysis published in the Journal of the American Heart Assn. last December suggested that PAD patients treated with paclitaxel-coated […]
- 1
- 2
- 3
- …
- 139
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube